Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 3, 2009, Pages 1170-1176

  Mirochnick, Mark ^a   Thomas, Timothy ^b   Capparelli, Edmund ^c   Zeh, Clement ^b   Holland, Diane ^c   Masaba, Rose ^b   Odhiambo, Prisea ^b   Fowler, Mary Glenn ^d   Weidle, Paul J ^e   Thigpen, Michael C ^e  

^a BOSTON MEDICAL CENTER   (United States)

^b KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MAKERERE UNIVERSITY   (Uganda)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; NEVIRAPINE; UNCLASSIFIED DRUG; VIRAMMUNE; ZIDOVUDINE;

ADULT; ARTICLE; BREAST FEEDING; CLINICAL TRIAL; DELIVERY; DRUG BLOOD LEVEL; DRUG MILK LEVEL; FEMALE; GESTATIONAL AGE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; INTRAPARTUM CARE; MAJOR CLINICAL STUDY; MALE; MATERNAL PLASMA; NEWBORN INFECTION; PHASE 2 CLINICAL TRIAL; PLACENTAL TRANSFER; PRENATAL CARE; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PUERPERIUM; SINGLE DRUG DOSE;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOOD; BREAST FEEDING; CLINICAL TRIALS, PHASE II AS TOPIC; DESICCATION; FEMALE; HIV INFECTIONS; HUMANS; INFANT; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; LACTATION; LAMIVUDINE; NEVIRAPINE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; REVERSE TRANSCRIPTASE INHIBITORS; YOUNG ADULT; ZIDOVUDINE;

EID: 62949168283     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01117-08     Document Type: Article

References (35)

1. Back, D., T. Blaschke, C. Boucher, et al. 2006. Optimizing TDM in HIV clinical care. http://www.hivpharmacology.com
2. Bailey, B., and S. Ito. 1997. Breast-feeding and maternal drug use. Pediatr. Clin. N. Am. 44:41-54.
3. Boucher, F. D., J. F. Modlin, S. Weller, A. Ruff, M. Mirochnick, S. Pelton, C. Wilfert, R. McKinney, Jr., M. J. Crain, M. M. Elkins, et al. 1993. Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus. J. Pediatr. 122:137-144.
4. Coates, J. A., N. Cammack, H. J. Jenkins on, A. J. Jowett, M. I. Jowett, B. A. Pearson, C. R. Penn, P. L. Rouse, K. C. Viner, and J. M. Cameron. 1992. (-)-2'-Deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrob. Agents Chemother. 36:733-739.
5. Colebunders, R., B. Hodossy, D. Burger, T. Daems, K. Roelens, M. Coppens, B. Van Bulck, Y. Jacquemyn, E. Van Wijngaerden, and K. Fransen. 2005. The effect of highly active antiretroviral treatment on viral load and antiretroviral drug levels in breast milk. AIDS 19:1912-1915.
6. Coutsoudis, A., F. Dabis, W. Fawzi, P. Gaillard, G. Haverkamp, D. R. Harris, J. B. Jackson, V. Leroy, N. Meda, P. Msellati, M. L, Newell, R. Nsuati, J. S. Read, and S. Wiktor. 2004. Late postnatal transmission of HIV-1 in breastfed children: an individual patient data meta-analysis. J. Infect. Dis. 189: 2154-2166.
7. De Cock, K. M., M. G. Fowler, E. Mercier, I. de Vincenzi, J. Saba, E. Hoff, D. J. Alnwick, M. Rogers, and N. Shaffer. 2000. Prevention of mother-to- child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA 283:1175-1182.
8. Giuliano, M., G. Guidotti, M. Andreotti, M. F. Pirillo, P. Villani, G. Liotta, M. C. Marazzi, M. G. Mancini, M. Cusato, P. Germano, S. Loureiro, S. Ceffa, M. Regazzi, S. Vella, and L. Palombi. 2007. Triple antiretroviral prophylaxis administered during pregnancy and after delivery significantly reduces breast milk viral load: a study within the Drug Resource Enhancement Against AIDS and Malnutrition Program. J. Acquir. Immune Defic. Svndr. 44:286-291.
9. Guay, L. A., P. Musoke, T. Fleming, D, Bagenda, M, Allen, C. Nakabiito, J. Sherman, P. Bakaki, C. Ducar, M. Deseyve, L. Emel, M. Mirochnick, M. G. Fowler, L. Mofenson, P. Miotti, K. Dransfleld, D. Bray, F. Mmiro, and J. B. Jackson. 1999. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala. Uganda: HIVNET 012 randomised trial. Lancet 354:795-802.
10. Havlir, D., S. H. Cheeseman, M. McLaughlin, R. Murphy, A. Erice, S. A. Spector, T. C. Greenough, J. L. Sullivan, D. Hall, M. Myers, et al. 1995. High-dose nevirapine: safety, pharmacokinetics, and antiviral eifect in patients with human immunodeficiency virus infection. J. Infect. Dis. 171:537- 545.
11. Holland, D. T., R. DiFrancesco, J. D. Connor, and G. D. Morse. 2006. Quality assurance program for pharmacokinetic assay of antiretrovirals: ACTG proficiency testing for pediatric and adult pharmacology support laboratories, 2003 to 2004: a requirement for therapeutic drug monitoring. Ther. Drug Monit. 28:367-374.
12. Kent, J. C., L. Mitoulas, D. B. Cox, R A. Owens, and R. E. Hartmann. 1999. Breast volume and milk production during extended lactation in women. Exp. Physiol. 84:435-447.
13. Kumwenda, N. I., D. R. Hoover, L. M. Mofenson, M. C. Thigpen, G. Kafulafula, Q. Li, L. Mipando, K. Nkanaunena, T. Mebrahtu, M. Bulterys, M. G. Fowler, and T. E. Taha. 2008. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N. Engl. J. Med. 359:119-129.
14. McNamara, P. J., and M. Abbassi. 2004. Neonatal exposure to drugs in breast milk. Pharm. Res. 21:555-566.
15. Mei, J. V., J. R. Alexander, B. W. Adam, and W. H. Hannon. 2001. Use of filter paper for the collection and analysis of human whole blood specimens. J. Nutr. 131:1631S-1636S.
16. Mei, J. V., W. H. Hannon, T. L. Dobbs, C. J. Bell, C. Spruill, and M. Gwinn. 1998. Radioimmunoassay for monitoring zidovudine in dried blood spot specimens. Clin. Chem. 44:281-286.
17. Mirochnick, M., E. Capparelli, K. Nielsen, J. Pilotto, P. Musoke, A. Shetty, and K. Luzuriaga. 2006. Nevirapine pharmacokinetics during the first year of life: a population analysis across studies, abstr. E-PAS2006:59:5523. 135. Abstr. Pediatr. Acad. Soc. Meet., San Francisco, CA.
18. Mirochnick, M., S. Siminski, T. Fenton, M. Lugo, and J. L. Sullivan. 2001. Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure. Pediatr. Infect. Dis. J. 20:803-805.
19. Moodley, J., D. Moodley, K. Pillay, H. Coovadia, J. Saba, R. van Leeuwen, C. Goodwin, P. R. Harrigan, K. H. Moore, C. Stone, R Plumb, and M. A. Johnson. 1998. Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J. Infect. Dis. 178:1327-1333.
20. Moorthy, A., A. Gupta, R. Bhosale, S. Tripathy, J. Sastry, S. Kulkarni, M. Thakar, R Bharadwaj, A. Kagal, A. V. Bhore, S. Patil, V. Kulkarni, V. Venkataramani, U. Balasubramaniam, N. Suryavanshi, C. Ziemniak, N. Gupte, R. Bollinger, and D. Persaud. 2009. Nevirapine resistance and breast- milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants. PLoS ONE 4:e4096.
21. Musoke, P., L. A. Guay, D. Bagenda, M. Mirochnick, C. Nakabiito, T. Fleming, T. Elliott, S. Horton, K. Dransfleld, J. W. Pav, A. Murarka, M. Allen, M. G. Fowler, L. Mofenson, D. Horn, F. Mmiro, and J. B. Jackson. 1999. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-l-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS 13:479-486.
22. Naver, L., S. Lindgren, E. Belfrage, K. Gyllensten, K. Lidman, M. Gisslen, A. Ehrnst, M. Arneborn, and A. B. Bohlin. 2006. Children born to HIV-l- infected women in Sweden in 1982-2003: trends in epidemiology and vertical transmission. J. Acquir. Immune Deflc. Syndr. 42:484-489.
23. Nduati, R., G. John, D. Mbori-Ngacha, B. Richardson, J. Overbaugh, A. Mwatha, J. Ndinya-Achola, J. Bwayo, F. E. Onyango, J. Hughes, and J. Kreiss. 2000. Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. JAMA 283:1167-1174.
24. O'Sullivan, M. J., P. J. Boyer, G. B. Scott, W. P. Parks, S. Weller, M. R. Blum, J. Balsley, Y. J. Bryson, et al. 1993. The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082). Am. J. Obstet Gynecol. 168:1510-1516.
25. Ruprecht, R. M., A. H. Sharpe, R. Jaenisch, and D. Trites. 1990. Analysis of 3'-azido-3'-deoxythymidine levels in tissues and milk by isocratic high-performance liquid chromatography. J. Chromatogr. 528:371-383.
26. Schneider, S., A. Peltier, A. Gras, V. Arendt, C. Karasi-Omes, A. Mujawamariwa, P. C. Ndimubanzi, G. Ndayisaba, and R. Wennig. 2008. Efavirenz in human breast milk, mothers', and newborns' plasma. J. Acquir. Immune Defic. Syndr. 48:450-454.
27. Shapiro, R. L., D. T. Holland, E. Capparelli, S. Lockman, I. Thior, C. Wester, L. Stevens, T. Peter, M. Essex, J. D. Connor, and M. Mirochnick. 2005. Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment. J. Infect. Dis. 192:720-727.
28. Shapiro, R. L., T. Ndung'u, S. Lockman, L. M. Smeaton, I. Thior, C. Wester, L. Stevens, G. Sebetso, S. Gaseitsiwe, T. Peter, and M. Essex. 2005. Highly active antiretroviral therapy started during pregnancy or postpartum suppresses HIV-1 RNA, but not DNA. in breast milk. J. Infect. Dis. 192:713- 719.
29. Shetty, A. K., H. M. Coovadia, M. M. Mirochnick, Y. Maldonado, L. M. Mofenson, S. H. Eshleman, T. Fleming, L. Emel, K. George, D. A. Katzen- stein, J. Wells, C. C. Maponga, A. Mwatha, S. A. Jones, S. S. Abdool Karim, and M. T. Bassett. 2003. Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 months. J. Acquir. Immune Defic. Syndr. 34:482-490.
30. Sinkala, M., L, Kuhn, C. Kankasa, P. Kasonde, C. Vwalika, M. Mwiya, N. Scott, K. Semrau, G. Aldrovani, D. Thea, and Z. E. B. S. Group. 2007. No benefit of early cessation of breastfeeding at 4 months on HIV-free survival of infants born to HIV-infected mothers in Zambia: the Zambia Exclusive Breastfeeding Study, abstr. 74LB. 14th Conf. Retrovir. Opportun. Infect., Los Angeles, CA
31. Thomas, T., R. Masaba, R. Ndivo, C. Zeh, C. Borkowf, M. Thigpen, et al. 2008. PMTCT of HIV-1 among breastfeeding mothers using HAART: the Kisumu breastfeeding study, Kisumu, Kenya, 2003-2007, abstr. 45aLB. Abstr. 15th Conf. Retrovir. Opportun. Infect., Boston, MA.
32. Tremoulet, A. H., E. V. Capparelli, P. Patel, E. P. Acosta, K. Luzuriaga, Y. Bryson, D. Wara, C. Zorrilla, D. Holland, and M. Mirochnick. 2007. Population pharmacokinetics of lamivudine in human immunodeficiency virusexposed and -infected infants. Antimicrob. Agents Chemother. 51:4297- 4302.
33. Wilfert, C. M., and M. G. Fowler. 2007. Balancing maternal and infant benefits and the consequences of breast-feeding in the developing world during the era of HIV infection. J. Infect. Dis. 195:165-167.
34. Wilson, J. T., R. D. Brown, J. L. Hinson, and J. W. Dailey. 1985. Pharmacokinetic pitfalls in the estimation of the breast milk/plasma ratio for drugs. Annu. Rev. Pharmacol. Toxicol. 25:667-689.
35. Zeh, C., P. Weidle, L. Nafisa, H. Musuluma, J. Okonji, E. Anyango, P. Bondo, R. Masaba, M. Thigpen, and T. Thomas. 2008. Emergence of HIV-1 drug resistance among breastfeeding infants born to HIV-infected mothers taking antiretrovirals for prevention of mother-to-child transmission of HIV: the Kisumu Breastfeeding Study, Kenya, abstr. 84LB. 15th Conf. Retrovir. Opportun. Infect., Boston, MA.